By ,
Published December 07, 2016
Bristol-Myers Squibb's immunotherapy drug Opdivo has been approved in Europe for the treatment of classical Hodgkin lymphoma, a rare blood cancer, the U.S. company said on Wednesday.
Opdivo is already approved for melanoma, lung cancer and kidney cancer.
https://www.foxnews.com/health/eu-clears-bristol-myers-immunotherapy-drug-for-blood-cancer